| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10909723 | Leukemia Research | 2005 | 10 Pages |
Abstract
The consequence of these findings is that combination of tyrosine kinase inhibitors with antileukemic drugs is likely to have the added beneficial effect of allowing MDR-type drugs better access to cells.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Daniella Yeheskely-Hayon, Ronit Regev, Gera D. Eytan, Eldad J. Dann,